252 related articles for article (PubMed ID: 21677477)
1. [Tykerb for breast cancer].
Suzuki Y; Saito Y; Okamura T; Tokuda Y
Gan To Kagaku Ryoho; 2011 Jun; 38(6):892-5. PubMed ID: 21677477
[TBL] [Abstract][Full Text] [Related]
2. Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions.
Nanda R
Rev Recent Clin Trials; 2007 May; 2(2):111-6. PubMed ID: 18473995
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Albanell J; Codony J; Rovira A; Mellado B; Gascón P
Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.
Frampton JE
Drugs; 2009 Oct; 69(15):2125-48. PubMed ID: 19791830
[TBL] [Abstract][Full Text] [Related]
5. [Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Pikó B
Magy Onkol; 2009 Dec; 53(4):369-75. PubMed ID: 20071309
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
7. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
8. HER2-positive breast cancer: current and future treatment strategies.
Engel RH; Kaklamani VG
Drugs; 2007; 67(9):1329-41. PubMed ID: 17547474
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib in metastatic breast cancer.
Frenel JS; Bourbouloux E; Berton-Rigaud D; Sadot-Lebouvier S; Zanetti A; Campone M
Womens Health (Lond); 2009 Nov; 5(6):603-12. PubMed ID: 19863462
[TBL] [Abstract][Full Text] [Related]
10. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
11. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
12. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
[TBL] [Abstract][Full Text] [Related]
13. HER2-positive breast cancer: beyond trastuzumab.
Murphy CG; Fornier M
Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
[TBL] [Abstract][Full Text] [Related]
14. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
15. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.
Ghosh R; Narasanna A; Wang SE; Liu S; Chakrabarty A; Balko JM; González-Angulo AM; Mills GB; Penuel E; Winslow J; Sperinde J; Dua R; Pidaparthi S; Mukherjee A; Leitzel K; Kostler WJ; Lipton A; Bates M; Arteaga CL
Cancer Res; 2011 Mar; 71(5):1871-82. PubMed ID: 21324925
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib: a competitor or companion to trastuzumab?
Collins D; Hill AD; Young L
Cancer Treat Rev; 2009 Nov; 35(7):574-81. PubMed ID: 19748186
[TBL] [Abstract][Full Text] [Related]
18. HER-2-positive breast cancer: hope beyond trastuzumab.
Bartsch R; Wenzel C; Zielinski CC; Steger GG
BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib: a sword with two edges.
Kopper L
Pathol Oncol Res; 2008 Mar; 14(1):1-8. PubMed ID: 18409020
[TBL] [Abstract][Full Text] [Related]
20. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.
Lin A; Rugo HS
Curr Treat Options Oncol; 2007 Feb; 8(1):47-60. PubMed ID: 17660958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]